Oncocyte (IMDX) Stock Price, News & Analysis

Company Overview

Oncocyte (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.

Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows. Its offerings are positioned to support physicians by reducing diagnostic uncertainty, guiding the need for invasive procedures, and helping to prioritize patients for additional testing or treatment. The company pursues clinical validation and regulatory review as part of its path to broader commercial adoption.

Headquartered in the United States, Oncocyte distributes its tests through clinical laboratory networks and strategic partnerships aimed at reaching physicians and healthcare systems. As a publicly listed company on the NASDAQ (IMDX), it concentrates on advancing its diagnostic pipeline, expanding commercial operations, and engaging with payors and clinical stakeholders to integrate its assays into standard oncology care pathways. Information on individual executives and recent leadership changes should be confirmed from the company’s filings and official communications for the most current details.

Key Stats

• Today's Range: $5.50 to $5.93
• 50-Day Range: $2.55 to $6.53
• 52-Week Range: $2.33 to $8.51
• Volume: 77,553 shs
• Average Volume: 233,340 shs
• Market Capitalization: $182.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Hold

Oncocyte Stock Analysis - MarketRank™

Oncocyte scored higher than 57% of companies evaluated by MarketBeat, and ranked 38th out of 87 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Oncocyte has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Oncocyte has a consensus price target of $12.00, representing about 105.1% upside from its current price of $5.85.

Amount of Analyst Coverage

Oncocyte has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Oncocyte is -3.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oncocyte is -3.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.74% of the float of Oncocyte has been sold short.

Short Interest Ratio / Days to Cover

Oncocyte has a short interest ratio ("days to cover") of 2.11, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oncocyte has recently increased by 65.88%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oncocyte does not currently pay a dividend.

Dividend Growth

Oncocyte does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.44

News Sentiment

Oncocyte has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Manufacturing companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Oncocyte this week, compared to 1 article on an average week.

Search Interest

4 people have searched for IMDX on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $2,685,120.00 in company stock, which represents 1.4215% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Oncocyte insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,685,120.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

2.05% of the stock of Oncocyte is held by insiders.

Percentage Held by Institutions

55.35% of the stock of Oncocyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/13/2026
• Today: 6/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: In Vitro, In Vivo Diagnostic Substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IMDX
• CIK: 1642380
• Web: N/A
• Phone: (949) 409-7600
• Fax: 510-521-3389
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Oncocyte: $12.00
• High Price Target: $12.00
• Low Price Target: $12.00
• Potential Upside/Downside: +114.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$50.22 million
• Net Margins: -2,454.64%
• Pretax Margin: -2,454.64%
• Return on Equity: N/A
• Return on Assets: -96.96%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.54
• Quick Ratio: 2.51

Sales & Book Value

• Annual Sales: $4.05 million
• Price / Sales: 44.65
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.10) per share
• Price / Book: -5.09

Miscellaneous

• Outstanding Shares: 32,290,000
• Free Float: 31,628,000
• Market Cap: $180.82 million
• Optionable: N/A
• Beta: 1.79